EP Patent

EP2965753A1 — Osmotic device containing amantadine and an osmotic salt

Assigned to Osmotica Kereskedelmi es Szolgaltato KFT · Expires 2016-01-13 · 10y expired

What this patent protects

A controlled release oral dosage form comprising a controlled release composition containing amantadine, or salt thereof, wherein the composition provides a controlled release of amantadine, or salt thereof, over a period of 8 hours up to 12 hours, 16 hours, 18 hours, 20 hours or…

USPTO Abstract

A controlled release oral dosage form comprising a controlled release composition containing amantadine, or salt thereof, wherein the composition provides a controlled release of amantadine, or salt thereof, over a period of 8 hours up to 12 hours, 16 hours, 18 hours, 20 hours or a day, or more than a day, and wherein the controlled release begins within a few minutes after administration or after expiration of a delay period after administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP2965753A1
Jurisdiction
EP
Classification
—
Expires
2016-01-13
Drug substance claim
No
Drug product claim
No
Assignee
Osmotica Kereskedelmi es Szolgaltato KFT
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.